{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:48:47Z","timestamp":1792540127904,"version":"4.5.0"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T00:00:00Z","timestamp":1451952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0143490","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T19:03:38Z","timestamp":1452020618000},"page":"e0143490","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":61,"title":["Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial"],"prefix":"10.1371","volume":"11","author":[{"given":"Robert C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revital","family":"Amiaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Mei","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Maayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Boules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Sershen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Youseff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Lajtha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Guidotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,1,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo smoking cessation","volume":"296","author":"D Gonzales","year":"2006","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, and alpha4beta2 nicotinic acetylcholine receptor partial agonist,vs placebo or sustained-release bupropion for smoking cessation","volume":"296","author":"D Jorenby","year":"2006","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a parietal agonist at {alpha]4{beta}2 and a full agonist at {alpha}7 neuronal nicotinic receptors","volume":"70","author":"K Mihakak","year":"2006","journal-title":"Mol Pharmcol"},{"issue":"3\u20134","key":"ref4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0891-0618(00)00109-5","article-title":"The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia","volume":"20","author":"R Freedman","year":"2000","journal-title":"Journal of Chemical Neuroanatomy"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","article-title":"Evidence in postmortem brain tissue for decreased numbers of hippocampus nicotinic receptors in schizophrenia","volume":"38","author":"R Freedman","year":"1995","journal-title":"Biological Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archpsyc.59.12.1085","article-title":"Association of Promoter Variants in the alpha-7 nicotinic acetylcholine receptor subunit gene with inhibitory deficit found in schizophrenia","volume":"59","author":"S Leonard","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1176\/ajp.150.12.1856","article-title":"Normalization of auditory physiology by cigarette smoking in schizophrenic patients","volume":"150","author":"LE Adler","year":"1993","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.schbul.a033320","article-title":"Schizophrenia, sensory gating, and nicotinic receptors","volume":"24","author":"LE Adler","year":"1998","journal-title":"Schizophrenia Bulletin"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.npp.1300881","article-title":"Effects of nicotine nasal spray on cognitive function in schizophrenia","volume":"31","author":"R Smith","year":"2006","journal-title":"Neuropsychoharmacology"},{"key":"ref10","first-page":"479","article-title":"Effects of cigarette smoking on psychopathology scores in schizophrenic patients: An experimental study","volume":"22","author":"RC Smith","year":"2002","journal-title":"Substance Abuse"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0893-133X(02)00324-X","article-title":"Effects of smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia","volume":"27","author":"RC Smith","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0893-133X(02)00372-X","article-title":"Nicotine and behavioral markers of risk for schizophrenia: a double-blind placebo-controlled, cross-over study","volume":"27","author":"l Depatie","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"ref13","first-page":"75","article-title":"Effects of smoking abstinence on visuospatial working memory function in schizophrenia","volume":"26","author":"T George","year":"2002","journal-title":"Neuropharmacology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0893-133X(96)00018-8","article-title":"Nicotine-haloperidol interactions and cogntive performance in schizophrenics","volume":"15","author":"ED Levin","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.npp.1301423","article-title":"The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls","volume":"33","author":"RS Barr","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00213-008-1133-8","article-title":"Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia","volume":"199","author":"LE Jubelt","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.schres.2009.02.001","article-title":"Cognitive and antismoking effects of varenicline in patients With schizophrenia or schizoaffective disorder","volume":"110","author":"RC Smith","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2011.83","article-title":"Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder","volume":"68","author":"LE Hong","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"J-C Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.jcp.0000162802.54076.18","article-title":"A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia","volume":"25","author":"A Evins","year":"2005","journal-title":"J Clin Psychopharm"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/01.jcp.0b013e3180ca86fa","article-title":"A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia","volume":"27","author":"AE Evins","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14622200020032051","article-title":"Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings","volume":"3","author":"LS Cox","year":"2001","journal-title":"Nicotine Tob Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.npp.1300030","article-title":"A self-administered questionnaire to measure dependence on cigarettes: The cigarette dependence scale","volume":"28","author":"J-F Ettner","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"SR Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"ref25","article-title":"The Scale for Assessment of Negative Symptoms (SANS)","author":"N Andreasen","year":"1983"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"D Addington","year":"1990","journal-title":"Schizophrenia Research"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000073452","article-title":"Dissociation between inattentiveness during mental status testing and social inattentiveness in the Scale for the Assessment of Negative Symptoms attention subscale","volume":"36","author":"EC Atbasoglu","year":"2003","journal-title":"Psychopathology"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1176\/ajp.156.12.1944","article-title":"Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity","volume":"156","author":"JM Gold","year":"1999","journal-title":"Am J Psychiatry"},{"key":"ref29","article-title":"The MATRICS Consensus Cognitive Battery, Part 2: co-Norming and Standardization","author":"R Kern","year":"2008","journal-title":"The MATRICS Consensus Cognitive Battery, Part 2: co-Norming and Standardization"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/npp.2010.101","article-title":"Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine","volume":"35","author":"E Weiner","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling for the false discovery Rate: A practical and power approach to multiple testing","volume":"57","author":"Y Benjamini","year":"1995","journal-title":"J Royal Statistical Soc"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","article-title":"The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization","volume":"165","author":"RS Kern","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jagp.2012.10.011","article-title":"Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS consensus cognitive battery","volume":"21","author":"TK Rajji","year":"2013","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.166.15.1561","article-title":"Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist:results from a 7-week randomized placebo and bupropion-controlled trial with 1-year follow-up","volume":"166","author":"M Nides","year":"2006","journal-title":"Arch Intern Med"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/15504263.2012.663675","article-title":"Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial","volume":"8","author":"GN Pachas","year":"2012","journal-title":"J Dual Diagn"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.11m07522","article-title":"A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder","volume":"73","author":"JM Williams","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.2013.285113","article-title":"Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial","volume":"311","author":"AE Evins","year":"2014","journal-title":"Jama"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.4088\/JCP.v69n0620a","article-title":"Varenicline treatment for smokers with schizophrenia","volume":"69","author":"AE Evins","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00213-013-3286-3","article-title":"Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia","volume":"231","author":"S Roh","year":"2014","journal-title":"Psychopharmacology"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.biopsych.2008.08.028","article-title":"Varenicline improves mood and cognition during smoking abstinence","volume":"65","author":"F Patterson","year":"2009","journal-title":"Biol Psychiatry"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.psychres.2011.04.018","article-title":"Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia","volume":"190","author":"M-E Liu","year":"2011","journal-title":"Psychiatry research"},{"issue":"1\u20133","key":"ref42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.schres.2013.06.032","article-title":"Varenicline modulates spatial working memory deficits in smokers with schizophrenia","volume":"149","author":"VC Wing","year":"2013","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"ref43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2010.09.015","article-title":"Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial","volume":"125","author":"RS Keefe","year":"2011","journal-title":"Schizophr Res"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.schres.2014.08.004","article-title":"Limited practice effects and evaluation of expectation for change: MATRICS Consensus Cognitive Battery","volume":"159","author":"JE Roseberry","year":"2014","journal-title":"Schizophr Res"},{"issue":"2","key":"ref45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1517\/14728222.2013.736498","article-title":"Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia","volume":"17","author":"TL Wallace","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":"Varenicline: An alpha\/beta2 nicotinic receptor partial agonist for smoking cessation","volume":"43","author":"J Coe","year":"2005","journal-title":"J Med Chem"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":"Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation","volume":"48","author":"JW Coe","year":"2005","journal-title":"J Med Chem"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuropharm.2006.10.016","article-title":"Pharmacological profile of \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist varenicline an effective smoking cessation aid","volume":"52","author":"H Rollema","year":"2007","journal-title":"Neuropharmacology"},{"issue":"8","key":"ref49","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1176\/appi.ajp.2007.07020326","article-title":"Exacerbation of schizophrenia by varenicline","volume":"164","author":"R Freedman","year":"2007","journal-title":"Am J Psychiatry"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1345\/aph.1K511","article-title":"Hypomania and agitation associated with varenicline use in bipolar II disorder","volume":"42","author":"AE Morstad","year":"2008","journal-title":"The Annals of Pharmacotherapy"},{"issue":"7","key":"ref51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40264-013-0046-6","article-title":"Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England","volume":"36","author":"Y Buggy","year":"2013","journal-title":"Drug Saf"},{"key":"ref52","first-page":"21","article-title":"Effect of Varenicline on Individual Nicotine Withdrawal Symptoms: A Combined Analysis of Eight Randomized, Placebo-Controlled Trials","volume":"21","author":"J Foulds","year":"2013","journal-title":"Nicotine Tob Res"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2165\/00002018-200932060-00006","article-title":"Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study","volume":"32","author":"R Kasliwal","year":"2009","journal-title":"Drug Safety; An International Journal of Medical Toxicology and Drug Experience"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/11319180-000000000-00000","article-title":"Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis","volume":"33","author":"S Tonstad","year":"2010","journal-title":"Drug safety"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1176\/appi.ajp.2013.12121599","article-title":"Varenicline, smoking cessation, and neuropsychiatric adverse events","volume":"170","author":"RD Gibbons","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"7","key":"ref56","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4088\/JCP.08m04441","article-title":"Varenicline augmentation in depressed smokers: an 8-week, open-label study","volume":"70","author":"NS Philip","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"ref57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-159-6-201309170-00005","article-title":"Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial","volume":"159","author":"RM Anthenelli","year":"2013","journal-title":"Annals of internal medicine"},{"issue":"3","key":"ref58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0920-9964(99)00129-2","article-title":"Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS)","volume":"42","author":"C Lancon","year":"2000","journal-title":"Schizophr Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0143490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T16:39:44Z","timestamp":1718296784000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0143490"}},"subtitle":[],"editor":[{"given":"Ingmar H.A.","family":"Franken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,5]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0143490","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,5]]}}}